Cohen J - Search Results

1

An ImmunoChip study of multiple sclerosis risk in African Americans.

Isobe N, Madireddy L, Khankhanian P, Matsushita T, Caillier SJ, Moré JM, Gourraud PA, McCauley JL, Beecham AH; International Multiple Sclerosis Genetics Consortium; Piccio L, Herbert J, Khan O, Cohen J, Stone L, Santaniello A, Cree BA, Onengut-Gumuscu S, Rich SS, Hauser SL, Sawcer S, Oksenberg JR. Isobe N, et al. Among authors: cohen j. Brain. 2015 Jun;138(Pt 6):1518-30. doi: 10.1093/brain/awv078. Epub 2015 Mar 28. Brain. 2015. PMID: 25818868 Free PMC article.

2

Loss of suppressor T cells in active multiple sclerosis. Analysis with monoclonal antibodies.

Reinherz EL, Weiner HL, Hauser SL, Cohen JA, Distaso JA, Schlossman SF. Reinherz EL, et al. Among authors: cohen ja. N Engl J Med. 1980 Jul 17;303(3):125-9. doi: 10.1056/NEJM198007173030303. N Engl J Med. 1980. PMID: 6446039

3

Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis.

Cree BA, Khan O, Bourdette D, Goodin DS, Cohen JA, Marrie RA, Glidden D, Weinstock-Guttman B, Reich D, Patterson N, Haines JL, Pericak-Vance M, DeLoa C, Oksenberg JR, Hauser SL. Cree BA, et al. Among authors: cohen ja. Neurology. 2004 Dec 14;63(11):2039-45. doi: 10.1212/01.wnl.0000145762.60562.5d. Neurology. 2004. PMID: 15596747

4

Emerging therapies for relapsing multiple sclerosis.

Cohen JA. Cohen JA. Arch Neurol. 2009 Jul;66(7):821-8. doi: 10.1001/archneurol.2009.104. Arch Neurol. 2009. PMID: 19597083 Review.

5

Combination therapy in multiple sclerosis.

Conway D, Cohen JA. Conway D, et al. Lancet Neurol. 2010 Mar;9(3):299-308. doi: 10.1016/S1474-4422(10)70007-7. Lancet Neurol. 2010. PMID: 20170843 Review.

6

Emerging oral therapies in multiple sclerosis.

Conway D, Cohen JA. Conway D, et al. Curr Neurol Neurosci Rep. 2010 Sep;10(5):381-8. doi: 10.1007/s11910-010-0125-3. Curr Neurol Neurosci Rep. 2010. PMID: 20549393

7

Multiple sclerosis: Mechanisms of disability accumulation in multiple sclerosis.

Conway DS, Cohen JA. Conway DS, et al. Nat Rev Neurol. 2010 Dec;6(12):654-5. doi: 10.1038/nrneurol.2010.175. Nat Rev Neurol. 2010. PMID: 21131915

8

Multiple sclerosis: advances in understanding pathogenesis and emergence of oral treatment options.

Bermel RA, Cohen JA. Bermel RA, et al. Lancet Neurol. 2011 Jan;10(1):4-5. doi: 10.1016/S1474-4422(10)70282-9. Lancet Neurol. 2011. PMID: 21163434 No abstract available.

9

Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis.

Cohen JA, Chun J. Cohen JA, et al. Ann Neurol. 2011 May;69(5):759-77. doi: 10.1002/ana.22426. Ann Neurol. 2011. PMID: 21520239 Review.

10

Randomized controlled trial of atorvastatin in clinically isolated syndrome: the STAyCIS study.

Waubant E, Pelletier D, Mass M, Cohen JA, Kita M, Cross A, Bar-Or A, Vollmer T, Racke M, Stüve O, Schwid S, Goodman A, Kachuck N, Preiningerova J, Weinstock-Guttman B, Calabresi PA, Miller A, Mokhtarani M, Iklé D, Murphy S, Kopetskie H, Ding L, Rosenberg E, Spencer C, Zamvil SS; ITN STAyCIS Study Group; ITN020AI Study Management Team. Waubant E, et al. Among authors: cohen ja. Neurology. 2012 Apr 10;78(15):1171-8. doi: 10.1212/WNL.0b013e31824f7fdd. Epub 2012 Mar 28. Neurology. 2012. PMID: 22459680 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

12,465 results

Search Page